About LAVA Therapeutics
LAVA Therapeutics NV (NASDAQ:LVTX) is a biotech firm focused on harnessing the power of its proprietary platform to develop a novel class of bispecific antibodies aimed at engaging gamma-delta T cells for the treatment of cancer. With a unique approach to cancer immunotherapy, LAVA targets a wide range of tumors by activating an innate immune response that is designed to selectively kill cancer cells. The company's pipeline is made up of several projects in varying stages of preclinical and clinical development, aiming to address the needs of patients with hard-to-treat cancers. LAVA Therapeutics is committed to pushing the boundaries of cancer treatment through ongoing research and development efforts, with the ultimate objective of improving patient outcomes and providing new therapeutic options for cancers with significant unmet medical needs.
Snapshot
Operations
Products and/or services of LAVA Therapeutics
- Development of bispecific gamma-delta T cell engagers targeting cancer cells.
- Research on innovative immunotherapies for solid tumors and hematological malignancies.
- Pipeline expansion focusing on Gammabody technology for precise immune system activation.
- Collaboration with partners to accelerate the development of novel cancer treatments.
- Investigation into the versatility and efficacy of bispecific antibodies in oncology.
- Advancement of preclinical studies to explore potential new therapeutic areas.
LAVA Therapeutics executive team
- Mr. Stephen Allen Hurly M.B.A., M.Sc.CEO, President & Executive Director
- Mr. Fred M. Powell CPAChief Financial Officer
- Dr. Charles Q. Morris M.D., MBChB, MRCP (UK), Ph.D.Chief Medical Officer
- Ms. Oxana Polyakova Ph.D.Chief Scientific Officer
- Ms. Amy Garabedian J.D.General Counsel & Corporate Secretary
- Dr. Hans van der Vliet M.D., Ph.D.Head of Innovation
- Dr. Ton Adang Ph.D.Chief Development Officer
- Mr. Owen P. Hughes Jr.Executive Director